Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 2 of 2 matches

Category 6 - PATHOLOGY SERVICES

Detection of measurable residual disease in patients with acute lymphoblastic leukaemia (MBS items 71202 and 73310)

Category 6 - PATHOLOGY SERVICES

73310

73310 - Additional Information

Item Start Date:
01-Nov-2023
Description Updated:
01-Nov-2023
Schedule Fee Updated:
01-Nov-2023

Group
P7 - Genetics

Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist

 



Fee: $1,550.00 Benefit: 75% = $1,162.50 85% = $1,451.30

(See para PN.0.35 of explanatory notes to this Category)

Results 1 to 2 of 2 matches


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change